0001104659-18-002075.txt : 20180112 0001104659-18-002075.hdr.sgml : 20180112 20180112163248 ACCESSION NUMBER: 0001104659-18-002075 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180111 FILED AS OF DATE: 20180112 DATE AS OF CHANGE: 20180112 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PATRICK GREGORY S CENTRAL INDEX KEY: 0001219844 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35518 FILM NUMBER: 18526294 MAIL ADDRESS: STREET 1: C/O SUPERNUS PHARMACEUTICALS, INC. STREET 2: 1550 EAST GUDE DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001356576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE BUSINESS ADDRESS: STREET 1: 1550 E GUDE DR CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-838-2500 MAIL ADDRESS: STREET 1: 1550 E GUDE DR CITY: ROCKVILLE STATE: MD ZIP: 20850 4 1 a4.xml 4 X0306 4 2018-01-11 0 0001356576 SUPERNUS PHARMACEUTICALS INC SUPN 0001219844 PATRICK GREGORY S C/O SUPERNUS PHARMACEUTICALS, INC. 1550 EAST GUDE DRIVE ROCKVILLE MD 20850 0 1 0 0 VP, Chief Financial Officer Common Stock 2018-01-11 4 M 0 25000 5.88 A 55975 D Common Stock 2018-01-11 4 M 0 20000 7.90 A 75975 D Common Stock 2018-01-11 4 M 0 30000 9.24 A 105975 D Common Stock 2018-01-11 4 S 0 50000 43.5629 D 55975 D Employee Stock Option (Right to Buy) 5.88 2018-01-11 4 M 0 25000 0 D 2021-12-30 Common Stock 25000 0 D Employee Stock Option (Right to Buy) 7.90 2018-01-11 4 M 0 20000 0 D 2023-02-05 Common Stock 20000 0 D Employee Stock Option (Right to Buy) 9.24 2018-01-11 4 M 0 30000 0 D 2024-01-21 Common Stock 30000 20000 D Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 12, 2017. Includes an aggregate of 259 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan subsequent to the date of the Reporting Person's most recent filing on Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.2500 to $43.8500, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. The option became exercisable in four equal installments beginning on December 30, 2012, which was the first anniversary of the date on which the option was granted. The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted. The option became exercisable in four equal installments beginning on January 21, 2015, which was the first anniversary of the date on which the option was granted. /s/ Gregory S. Patrick 2018-01-12